{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(3)"],"submitter":["Knopf P"],"funding":["Universitätsklinikum Tübingen"],"pubmed_abstract":["<h4>Purpose</h4>Resection of the tumor-draining lymph -node (TDLN) represents a standard method to identify metastasis for several malignancies. Interestingly, recent preclinical studies indicate that TDLN resection diminishes the efficacy of immune checkpoint inhibitor-based cancer immunotherapies. Thus, accurate preclinical identification of TDLNs is pivotal to uncovering the underlying immunological mechanisms. Therefore, we validated preclinically, and clinically available non-invasive in vivo imaging approaches for precise TDLN identification.<h4>Procedures</h4>For visualization of the lymphatic drainage into the TDLNs by non-invasive in vivo optical imaging, we injected the optical imaging contrast agents Patent Blue V (582.7 g mol<sup>-1</sup>) and IRDye® 800CW polyethylene glycol ("],"journal":["Molecular imaging and biology"],"pagination":["606-618"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10172276"],"repository":["biostudies-literature"],"pubmed_title":["Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach."],"pmcid":["PMC10172276"],"pubmed_authors":["Stowbur D","Hoffmann SHL","Schwenck J","Kneilling M","Fransen MF","Knopf P","Pichler BJ"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach.","description":"<h4>Purpose</h4>Resection of the tumor-draining lymph -node (TDLN) represents a standard method to identify metastasis for several malignancies. Interestingly, recent preclinical studies indicate that TDLN resection diminishes the efficacy of immune checkpoint inhibitor-based cancer immunotherapies. Thus, accurate preclinical identification of TDLNs is pivotal to uncovering the underlying immunological mechanisms. Therefore, we validated preclinically, and clinically available non-invasive in vivo imaging approaches for precise TDLN identification.<h4>Procedures</h4>For visualization of the lymphatic drainage into the TDLNs by non-invasive in vivo optical imaging, we injected the optical imaging contrast agents Patent Blue V (582.7 g mol<sup>-1</sup>) and IRDye® 800CW polyethylene glycol (","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-21T22:47:34.351Z","creation":"2025-04-05T18:50:50.702Z"},"accession":"S-EPMC10172276","cross_references":{"pubmed":["36600172"],"doi":["10.1007/s11307-022-01797-z"]}}